The Journal of Clinical Psychiatry

Information from Industry June 30, 2020

SPRAVATO® (esketamine) CIII Nasal Spray: The First and Only N-Methyl D-Aspartate (NMDA) Receptor Antagonist Approved in Conjunction With an Oral Antidepressant for the Treatment of Adults With Treatment-Resistant Depression

https://www.psychiatrist.com/esketamine-ciii-nasal-spray-treatment-resistant-depression/

From the Editors